Oncoinvent ASA (OL:ONCIN) — Market Cap & Net Worth
Market Cap & Net Worth: Oncoinvent ASA (ONCIN)
Oncoinvent ASA (OL:ONCIN) has a market capitalization of $21.91 Million (Nkr208.25 Million) as of May 22, 2026. Listed on the OL stock exchange, this Norway-based company holds position #24848 globally and #231 in its home market, demonstrating a -1.90% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Oncoinvent ASA's stock price Nkr46.50 by its total outstanding shares 4478412 (4.48 Million). Analyse Oncoinvent ASA operating cash flow efficiency to see how efficiently the company converts income to cash.
Oncoinvent ASA Market Cap History: 2025 to 2026
Oncoinvent ASA's market capitalization history from 2025 to 2026. Data shows growth from $231.39K to $21.91 Million (0.00% CAGR).
Oncoinvent ASA Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Oncoinvent ASA's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.01x
Oncoinvent ASA's market cap is 0.01 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2025 | $231.39K | $28.07 Million | -$155.07 Million | 0.01x | N/A |
Competitor Companies of ONCIN by Market Capitalization
Companies near Oncoinvent ASA in the global market cap rankings as of May 22, 2026.
Key companies related to Oncoinvent ASA by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #221 globally with a market cap of $110.03 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #414 globally with a market cap of $66.20 Billion USD.
- argenx NV ADR (NASDAQ:ARGX): Ranked #577 globally with a market cap of $45.97 Billion USD.
- UCB S.A. UNSP.ADR 1/2 (F:UNC0): Ranked #598 globally with a market cap of $44.84 Billion USD ( €38.35 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #221 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.03 Billion | $433.54 |
| #414 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $66.20 Billion | $642.59 |
| #577 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
| #598 | UCB S.A. UNSP.ADR 1/2 | F:UNC0 | $44.84 Billion | €120.00 |
Oncoinvent ASA Historical Marketcap From 2025 to 2026
Between 2025 and today, Oncoinvent ASA's market cap moved from $231.39K to $ 21.91 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Nkr21.91 Million | +9370.47% |
| 2025 | Nkr231.39K | -- |
End of Day Market Cap According to Different Sources
On May 22nd, 2026 the market cap of Oncoinvent ASA was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $21.91 Million USD |
| MoneyControl | $21.91 Million USD |
| MarketWatch | $21.91 Million USD |
| marketcap.company | $21.91 Million USD |
| Reuters | $21.91 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Oncoinvent ASA
Oncoinvent ASA, a clinical stage company, develops radiopharmaceutical therapies against cancer. Its lead product candidate is Radspherin, an alpha-radiation therapy candidate for treating cancer that have spread to body cavities, including peritoneum in two phase 1/2a trials and one randomized phase 2 trial. The company is based in Oslo, Norway.